Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide (Q37335047)

19 August 2017

1 reference

title

Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide (English)

1 reference

chronic renal insufficiency

19 August 2017

main subject

1 reference

Begoña López

1

0 references

author name string

Arantxa González

2

1 reference

19 August 2017

Nerea Hermida

3

1 reference

19 August 2017

Concepción Laviades

4

1 reference

19 August 2017

Javier Díez

5

1 reference

19 August 2017

publication date

1 December 2008

1 reference

Kidney International. Supplement

19 August 2017

published in

1 reference

19 August 2017

issue

111

1 reference

19 August 2017

page(s)

S19-23

1 reference

Cardiovascular changes in renal failure

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Morphology of the heart and arteries in renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Mechanisms of cardiac fibrosis in hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Hypoxic stress induces cardiotrophin-1 expression in cardiac myocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Clinical and echocardiographic disease in patients starting end-stage renal disease therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Congestive heart failure in chronic kidney disease: disease-specific mechanisms of systolic and diastolic heart failure and management

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Diastolic Function in Several Stages of Chronic Kidney Disease in Patients with Autosomal Dominant Polycystic Kidney Disease: A Tissue Doppler Imaging Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Dynamic assessment of myocardial involvement in patients with end-stage renal disease by ultrasonic tissue characterization and serum markers of collagen metabolism.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Impact of the angiotensin II receptor antagonist, losartan, on myocardial fibrosis in patients with end-stage renal disease: assessment by ultrasonic integrated backscatter and biochemical markers

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Transforming growth factor beta in hypertensives with cardiorenal damage

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Role of left ventricular stiffness in heart failure with normal ejection fraction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Chronic kidney disease associated mortality in diastolic versus systolic heart failure: a propensity matched study.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Left ventricular geometry and renal function in hypertensive patients with diastolic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insuffic

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Role of excess volume in the pathophysiology of hypertension in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Torasemide. An update of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Torasemide in chronic heart failure: results of the TORIC study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Effects of Torasemide on Left Ventricular Function and Neurohumoral Factors in Patients With Chronic Heart Failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Torasemide, a new potent diuretic. Double-blind comparison with furosemide

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Comparative effects of torasemide and furosemide in rats with heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Expression of procollagen C‐proteinase enhancer in cultured rat heart fibroblasts: Evidence for co‐regulation with type I collagen

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Transforming growth factor-beta regulation of bone morphogenetic protein-1/procollagen C-proteinase and related proteins in fibrogenic cells and keratinocytes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Torasemide inhibits transcardiac extraction of aldosterone in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Amino acid derived sulfonamide hydroxamates as inhibitors of procollagen C-proteinase: solid-phase synthesis of ornithine analogues

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Clinical effects of torasemide prolonged release in mild-to-moderate hypertension: a randomized noninferiority trial versus torasemide immediate release

1 reference

https://api.crossref.org/works/10.1038%2FKI.2008.512

7 January 2021

Identifiers

DOI

10.1038/KI.2008.512

1 reference

19 August 2017

1 reference